Hopantenic Acid
Pantogam, Pantogam Activ, Pantocalcin, homopantothenic acid, calcium hopantenate — the GABA analog of pantothenic acid
Hopantenic Acid (Pantogam, Pantogam Activ, Pantocalcin, homopantothenic acid, calcium hopantenate — the GABA analog of pantothenic acid) is a cognitive & mood research compound. Pantothenic acid with the beta-alanine replaced by GABA — one methylene group away from vitamin B5, which is exactly the problem and exactly the selling point. As a GABA analog with a bulky polar tail it is described as a weak GABA-B ligand, which is the nootropic story. As a pantothenate analog it competes with vitamin B5 for the pathway that builds coenzyme A, which is the story behind the only serious toxicity ever recorded for this family: a Japanese case series of acute encephalopathy with metabolic acidosis and severe hypoglycemia during calcium hopantenate.
Hopantenic Acid quick facts
| Route | Oral |
| Frequency | 2-3x Daily in the trials |
| Half-life | Not characterized in a published human pharmacokinetic study |
| Forms | Oral |
| Evidence level | A registered medicine in Russia and neighboring countries; unapproved everywhere else. Every controlled trial is Russian-language, and most are in children. |
The trial record is real and it is not about the reader. Two Russian multicenter double-blind placebo-controlled studies exist — one in children with attention deficit hyperactivity disorder, one in preterm infants with hypoxic-ischemic encephalopathy — plus open studies in adults with cerebrovascular disease. No controlled trial has been run in a healthy adult. The safety point is the one nobody in this market states: the calcium salt of the same acid produced a five-patient series of acute encephalopathy with metabolic acidosis and hypoglycemia, and the mechanism proposed for it is competition with vitamin B5 for coenzyme A synthesis.
How Hopantenic Acid works
Pantothenic acid with the beta-alanine replaced by GABA — one methylene group away from vitamin B5, which is exactly the problem and exactly the selling point. As a GABA analog with a bulky polar tail it is described as a weak GABA-B ligand, which is the nootropic story. As a pantothenate analog it competes with vitamin B5 for the pathway that builds coenzyme A, which is the story behind the only serious toxicity ever recorded for this family: a Japanese case series of acute encephalopathy with metabolic acidosis and severe hypoglycemia during calcium hopantenate.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Hopantenic Acid
Buy Hopantenic Acid at RUPharma →The evidence for Hopantenic Acid
Graded by what exists behind each claim.
✅ Clinically validated
- Two multicenter double-blind placebo-controlled trials exist and both are in children: hopantenic acid in attention deficit hyperactivity disorder over four months (Zavadenko 2017), and a double-blind comparative multicenter placebo-controlled study in 6-12 month preterm infants with hypoxic-ischemic encephalopathy, reporting improvement in 63.6% of treated patients (Zavadenko 2019).
- The adult studies use the racemate and are in diagnosed populations: cognitive and anxiety disorders in arterial hypertension (Smulevich 2015), and anxiety and depressive disorders in chronic cerebral ischemia (Gekht 2016).
- No controlled trial has been run in a healthy adult, and every trial is Russian-language and single-country.
📊 Correlative data
- GABA signaling in ischemia and reperfusion, in brain and peripheral organs, is the context most of that clinical work sits in (Chen 2019).
- The one documented serious toxicity in this family: five patients with acute encephalopathy, marked metabolic acidosis and severe hypoglycemia during calcium hopantenate administration, attributed to interference with coenzyme A synthesis (Ohsuga 1989).
🧪 Theoretical / extrapolated
- It is pantothenic acid with the beta-alanine replaced by GABA — one methylene group from vitamin B5, which is simultaneously the nootropic story and the toxicity story.
- As a pantothenate analog it competes for incorporation into coenzyme A, which fatty acid oxidation and carnitine-dependent transport both require. That chain is the proposed pathogenesis of the 1989 series.
- The three brands are not three brands of one drug. PANTOGAM is the calcium salt of the D-isomer; PANTOGAM ACTIVE is the racemate, a different composition with its own trials; PANTOCALCIN is calcium hopantenate again.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Hopantenic Acid actually does
One methylene group from vitamin B5, and that is both the mechanism and the toxicity. Pantothenic acid is beta-alanine joined to pantoic acid. Hopantenic acid replaces the beta-alanine with GABA — gamma-aminobutyric acid, one carbon longer. So the molecule is simultaneously a GABA derivative with a bulky polar tail and a structural analog of a vitamin, and both readings have consequences.
The nootropic reading. Attaching the pantoyl group to GABA makes a molecule that crosses membranes better than GABA itself, which is essentially excluded from the brain. It is described as a weak ligand at GABA-B receptors, and Chen 2019 reviews what GABA signaling does in ischemia and reperfusion in brain and peripheral organs — the context most of the Russian clinical work sits in. Weak is the operative word: this is not a benzodiazepine-like molecule and it does not behave as one.
The vitamin-analog reading, which is the one that matters. A pantothenate analog competes with pantothenate for incorporation into coenzyme A. Coenzyme A is required for fatty acid oxidation, for the citric acid cycle, and for carnitine-dependent transport of fatty acids into mitochondria. Interfere with it and the predicted consequences are a failure of fat oxidation, a shift to ketogenesis and lactate, and hypoglycemia when glucose runs out. That is not a theoretical chain: it is the proposed pathogenesis of Ohsuga 1989.
The three products are three different things and the shelf does not say so. PANTOGAM is the calcium salt of the D-isomer. PANTOGAM ACTIVE is the racemic acid, D- and L- together, which is a different molecule with different trials Smulevich 2015. PANTOCALCIN is calcium hopantenate again under a third brand. A reader comparing prices across the three is comparing two isomeric compositions, not three brands of one drug.
Cell, rodent, human — and where it stops
Two multicenter double-blind placebo-controlled trials exist, and both are in children. Zavadenko 2017 is a multicenter double-blind placebo-controlled study of hopantenic acid in attention deficit hyperactivity disorder in children, run over four months. Zavadenko 2019 is a double-blind comparative multicenter placebo-controlled study in 6 to 12 month preterm infants with hypoxic-ischemic encephalopathy, reporting improvement in 63.6% of treated patients. Those are real designs and they are the strongest evidence this molecule has.
The adult studies are in patients with cerebrovascular or psychiatric diagnoses, and they use the racemate. Smulevich 2015 studied D,L-hopantenic acid for cognitive and anxiety disorders in patients with arterial hypertension. Gekht 2016 examined rac-hopantenic acid in anxiety and depressive disorders in patients with chronic cerebral ischemia, reporting nootropic, antidepressant and anxiolytic effects. Both are in diagnosed populations, both are Russian-language, and neither is the D-isomer product sold most widely.
What the whole record has in common. Every controlled trial is Russian, published in one journal family, in populations with a diagnosis — children with ADHD, infants after hypoxic injury, adults with hypertension or cerebral ischemia. No controlled trial has been run in a healthy adult. That is not a criticism of the trials, which were done for the indications the drug is registered for. It is a statement about who the evidence is about.
The single-country problem, said once and honestly. A drug registered in one regulatory system, trialed by investigators within it, published in its own language, is harder for an outsider to weigh than a drug with an independent replication somewhere else. That is a reason for calibrated uncertainty rather than dismissal, and the replication has not happened.
Hopantenic Acid pharmacokinetics — how much of it actually gets in
What degrades it, and what it competes with on the way. Hopantenic acid is a small water-soluble carboxylic acid. It is not extensively metabolized by cytochromes; the disposition that matters is renal clearance and competition with pantothenate for the transporters and enzymes of the coenzyme A pathway. Its structural similarity to a vitamin is not a metabolic curiosity, it is the route by which the molecule interferes with something.
The oral barrier, and why this molecule does not have much of one. Small polar acids of this kind are absorbed from the gastrointestinal tract by carrier-mediated transport and are not subject to heavy first-pass metabolism, so oral bioavailability is not the limiting step. The limiting step is the blood-brain barrier, and the whole design rationale for hanging a pantoyl group on GABA is to get past it — a rationale that has never been confirmed by a published measurement of the compound in human cerebrospinal fluid.
No human pharmacokinetic study has been published, and that is the honest headline. No plasma concentration-time curve, no half-life, no renal clearance figure, no accumulation data in reduced kidney function. The trials dosed it two or three times a day, which implies a short duration of action but is a dosing convention rather than a measurement. Doses in the Russian pediatric literature run to gram-scale daily totals against tablets of 250 to 500 mg.
The comparator that does not exist. Hopantenic acid has never been given by injection in any published study, so no study can separate absorption from distribution and no bioavailability figure can be quoted. An injection would start with the whole dose already in blood; every number in this record starts behind the gut wall instead. The one quantitative human pharmacology in the entire record is Ohsuga 1989, and it is a toxicity series rather than a pharmacokinetic study — five patients, acute encephalopathy, metabolic acidosis and severe hypoglycemia during calcium hopantenate administration.
What would have to be true, and how you would know it was not
Four predictions, and the first is the one nobody in this market makes.
1. Carnitine, because the proposed toxicity runs through it. Coenzyme A depletion impairs fatty acid oxidation, and the hopantenate encephalopathy syndrome is described with carnitine deficiency as part of its mechanism Ohsuga 1989. A serum carnitine level is an ordinary send-out test. It is the mechanistically correct measurement for this molecule and it has never been reported in any of the efficacy trials.
2. A CMP, read for the anion gap rather than for the liver. Metabolic acidosis is the presenting abnormality in the toxicity series. Sodium, chloride and bicarbonate from a standard panel give the anion gap, which is the number that would show it. Prediction: normal in an adult on a short course, and the reason to name it is that the abnormality has a documented precedent.
3. A urinalysis for ketones, at almost no cost. If fatty acid oxidation is impaired, ketogenesis and lactate rise. A dipstick is cents. Prediction: negative, and a positive reading in someone who is eating normally is a reason to stop and be assessed rather than a curiosity.
4. Against the product: any adult cognitive claim rests on trials in children and in diagnosed patients. Zavadenko 2017 and Zavadenko 2019 are pediatric; Smulevich 2015 and Gekht 2016 are in adults with hypertension or chronic cerebral ischemia. The prediction that follows is that a trial in healthy adults would be null, and it is testable, and it has not been tested.
What nobody has tested yet
No human pharmacokinetics have been published at all. Not for either isomer, not for the racemate, not for the calcium salt. That means no half-life, no dose proportionality, no renal adjustment and no measurement of whether the compound reaches the central nervous system in a person — which is the drug's entire design rationale.
Nobody has compared the D-isomer with the racemate head to head. Two products are sold side by side at different prices with different isomeric compositions and separate trial literatures Zavadenko 2017 Smulevich 2015. Which is better, or whether the L-isomer contributes anything, has not been reported.
Nobody has quantified the coenzyme A effect at therapeutic doses. The toxicity series Ohsuga 1989 establishes that the pathway can be disturbed. Whether it is measurably disturbed at ordinary doses in ordinary adults is an unanswered question with an obvious experiment: serum carnitine and acylcarnitine profiles before and after a standard course.
Extrapolation, labeled as such. If the effect is GABA-B mediated Chen 2019, then it should be blocked by a GABA-B antagonist and should show cross-tolerance with other GABA-B agents. Neither prediction has been tested, and both are ordinary pharmacology experiments rather than research programs.
Hopantenic Acid — its own safety story, not its class's
Three things specific to a pantothenic acid analog.
The one documented serious toxicity in this family, with its mechanism. Ohsuga 1989 reports five patients who developed acute encephalopathy with marked metabolic acidosis and severe hypoglycemia during calcium hopantenate administration. The pathogenesis proposed is interference with coenzyme A synthesis and consequent failure of fatty acid oxidation. That is a Japanese case series from 1989 and it is the reason this molecule's regulatory history in Japan is different from its history in Russia. Nothing in this market mentions it.
Who that mechanism puts at the sharp end. Anything that already stresses fatty acid oxidation compounds it: prolonged fasting, a ketogenic diet, alcohol, intercurrent illness, and childhood, where hepatic glycogen reserves are smallest. The trials that support this drug were run in children, which is also the population in which the toxicity was described — and both facts belong on the same page.
The ordinary profile, and where the boundary is. The reported tolerability in the Russian trials is good, with sleep disturbance and agitation the usual complaints. What has never been characterized is long-term use, use alongside valproate or other drugs that affect carnitine handling, or use in anyone with an inherited disorder of fatty acid oxidation. Confusion, vomiting, unusual drowsiness or breathlessness on this drug are reasons to stop and seek assessment the same day. Nothing on this page is a diagnosis or a substitute for one.
Sources read for this page
- Zavadenko NN, Suvorinova NY, Vakula IN, Malinina EV, Kuzenkova LM. [Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2017 [Russian] · PMID 28638029
- Zavadenko NN, Guzeva VI, Gaynetdinova DD, Davydova LA, Zavadenko AN, Romanova TA. [Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2019 [Russian] · PMID 31793540
- Smulevich AB, Volel BA, Ternovaya ES, Nikitina YM. [Pantogam activ (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2015 [Russian] · PMID 26978493
- Gekht AB, Kanaeva LS, Avedisova AS, Marachev MP, Zakharova KV, Dashkina GK, Kulikova EV. [Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2016 [Russian] · PMID 28091501
- Ohsuga S, Ohsuga H, Takeoka T, Ikeda A, Shinohara Y. [Metabolic acidosis and hypoglycemia during calcium hopantenate administration--report on 5 patients]. Rinsho Shinkeigaku 1989 [Japanese] · PMID 2582687
- Chen C, Zhou X, He J, Xie Z, Xia S, Lu G. The Roles of GABA in Ischemia-Reperfusion Injury in the Central Nervous System and Peripheral Organs. Oxidative Medicine and Cellular Longevity 2019 · PMID 31814874
Hopantenic Acid — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Hopantenic Acid — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Hopantenic Acid moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Hopantenic Acid in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Hopantenic Acid
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Hopantenic Acid — frequently asked questions
What is Hopantenic Acid?
Hopantenic Acid (Pantogam, Pantogam Activ, Pantocalcin, homopantothenic acid, calcium hopantenate — the GABA analog of pantothenic acid) is a cognitive & mood research compound. Pantothenic acid with the beta-alanine replaced by GABA — one methylene group away from vitamin B5, which is exactly the problem and exactly the selling point. As a GABA analog with a bulky polar tail it is described as a weak GABA-B ligand, which is the nootropic story. As a pantothenate analog it competes with vitamin B5 for the pathway that builds coenzyme A, which is the story behind the only serious toxicity ever recorded for this family: a Japanese case series of acute encephalopathy with metabolic acidosis and severe hypoglycemia during calcium hopantenate.
Where can I find Hopantenic Acid dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Hopantenic Acid protocol are available to members inside Skool. This public page covers what Hopantenic Acid is, how it works and the evidence.
What is the half-life of Hopantenic Acid?
Hopantenic Acid has an approximate half-life of Not characterized in a published human pharmacokinetic study, which is part of what determines how often it's dosed.
What's the evidence behind Hopantenic Acid?
Current evidence level: A registered medicine in Russia and neighboring countries; unapproved everywhere else. Every controlled trial is Russian-language, and most are in children.. Hopantenic Acid is offered for research purposes only and is not an approved medicine.
What Hopantenic Acid is used for
Hopantenic Acid appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.